A
Alvotech (ALVO)
NGM – Real vaqt narxi. Valyuta: USD
3.68
+0.20 (5.75%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
3.74
+0.06 (1.63%)
Bozordan keyin: Jun 26, 2026, 6:15 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
3.68
+0.20 (5.75%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
3.74
+0.06 (1.63%)
Bozordan keyin: Jun 26, 2026, 6:15 PM EDT
Alvotech, sho'ba korxonalari orqali, dunyo bo'ylab bemorlar uchun biosimilar dorilarni ishlab chiqadi va ishlab chiqaradi. Kompaniya otoimmün, ko'z va suyak kasalliklari, shuningdek saraton kasalliklari sohalarida biosimilar mahsulotlarni taklif etadi. Kompaniya revmatoid artrit, psoriatik artrit, Kron kasalligi, ankilozan spondilit, yarali kolit va boshqa ko'rsatmalarni o'z ichiga olgan turli xil yallig'lanish holatlarini davolash uchun Humira'ga biosimilar bo'lgan yuqori konsentratsiyali, kam hajmli adalimumab formulasi bo'lgan AVT02; psoriatik artrit, Kron kasalligi, yarali kolit, blyashka psoriaz va boshqa ko'rsatmalarni o'z ichiga olgan turli xil yallig'lanish holatlarini davolash uchun Stelara'ga biosimilar bo'lgan AVT04; neovaskulyar yoshga bog'liq makula degeneratsiyasi, retinal ven trombozidan keyingi makula shishi, diabetik makula shishi va diabetik retinopatiya kabi turli xil holatlarni davolash uchun Eylea'ga biosimilar bo'lgan AVT06; va ma'lum turdagi saraton kasalligi bo'lgan bemorlarda suyak sinishi, orqa miya kompressiyasi va radiatsiya yoki suyak jarrohligi ehtiyojini oldini olish va davolash uchun Xgeva va Prolia'ga biosimilar bo'lgan AVT03, shuningdek suyak yo'qotilishining oldini olish va suyak massasini ko'paytirish uchun. Bundan tashqari, kompaniya revmatoid artrit, psoriatik artrit, yarali kolit va boshqa ko'rsatmalarni o'z ichiga olgan turli xil yallig'lanish holatlarini davolash uchun Simponi va Simponi Aria'ga biosimilar bo'lgan AVT05; o'rtacha yoki og'ir yarali kolit va o'rtacha yoki og'ir darajada faol bo'lgan Kron kasalligi bo'lgan kattalar bemorlarni davolash uchun Entyvio mahsulotiga biosimilar bo'lgan AVT16; allergik astma, surunkali spontan ürtiker (CSU) va burun polipi davolash uchun Xolair'ga biosimilar bo'lgan AVT23; va rivojlanishning dastlabki bosqichida bo'lgan Keytruda mahsulotiga biosimilar bo'lgan AVT33ni taklif etadi. Alvotech 2013-yilda tashkil etilgan va Lyuksemburg, Lyuksemburgda joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Anthony M. Maffia III | Chief Quality & Regulatory Officer |
| Mr. Benedikt Stefansson | Vice President of Investor Relations & Global Communications |
| Mr. Joseph E. McClellan | Chief Operating Officer |
| Mr. Vilhelm Robert Wessman | Founder & Executive Chairman |
| Ms. Kathryn Gunnarsson | Senior Vice President of Global Talent & People Experience |
| Ms. Linda Jonsdottir | Chief Financial Officer |
| Ms. Lisa Graver | Chief Executive Officer |
| Ms. Neha Patel | Chief Information Officer |
| Ms. Sarah Macleod | Head of Global Communications |
| Ms. Tanya Zharov | General Counsel |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-18 | 6-K | f6k_061826.htm |
| 2026-06-17 | 6-K | c116686_6k.htm |
| 2026-06-15 | 6-K | c116680_6k.htm |
| 2026-06-08 | 6-K | f6k_060826.htm |
| 2026-06-04 | 6-K | f6k_060426.htm |
| 2026-05-11 | 6-K | f6k_051126.htm |
| 2026-05-04 | 6-K | f6k_050426.htm |
| 2026-03-31 | 20-F | alvo-20251231.htm |
| 2026-03-19 | 6-K | f6k_031826.htm |
| 2026-02-27 | 6-K | f6k_022726.htm |